Dalriada Drug Discovery Inc.
$500,000.00 CAD
≈ 6 Canadians' average pay for a year
- Department
- National Research Council Canada
- Recipient country
- Canada
- Fiscal year
- 2025-2026
- Agreement period
- April 1, 2025 – March 30, 2027
- Reference
- nrc-cnrc:172-2025-2026-Q1-1028974
Published purpose
E!7296 COVANEXT: Unlocking druggability of disordered proteins Co-International partner: Nuage Therapeutics SL, Spain To advance the development of NT-A, a first-in-class covalent therapeutic for small cell lung cancer (SCLC).
Community tags
Tags are applied by readers, not by this site. One tag per person per record.
Good value
Local impact
Needs context
Questionable
Success story
Wasteful
View official source record
Imported July 30, 2026 from open.canada.ca Grants & Contributions